PMC-401S

**PMC-401S** is a preclinical **anti-angiopoietin-2 antibody fragment** being developed by **PharmAbcine** for ophthalmic vascular diseases, particularly **diabetic retinopathy** and **age-related macular degeneration**. It is described as a **fully human single-chain variable fragment** that selectively neutralizes **angiopoietin-2**, thereby blocking the **Ang2-Tie2** pathway while preserving **Ang1** interaction with **Tie2**. The intended effect is **vascular stabilization and normalization**, reducing pathologic vascular leakage and aberrant angiogenesis in retinal disease models. Publicly available information indicates that the asset remains in **preclinical or optimization-stage development**.

Other names

anti-ANG2 antagonistic fully human scFvanti-ANG-2 antagonistic fully human scFvanti-ANG 2 antagonistic fully human scFv